# BIOQUORA FOUNDER BIBLE
## Volume VII — Step 7: Drug Discovery, Translational Medicine & Precision Therapeutics Platform (Codename: BioDiscovery)
### Full Engineering Specification & Mechanistic Target Discovery Architecture
**Version:** 1.0.0-PROD  
**Classification:** Core Drug Discovery & Translational Therapeutics Specification (10-Year Horizon)  
**Target System:** BioDiscovery Target Prioritization Engine, Repurposing Platform, & ADMET Profiler  

---

## Executive Summary & Engineering Philosophy

If **Step 6 (BioMind)** gave Bioquora the ability to reason over multi-modal biomedical knowledge, **Step 7 (BioDiscovery)** transforms that reasoning into **Translational Therapeutics and Mechanistic Drug Discovery**.

BioDiscovery unifies Target Discovery (Open Targets / ChEMBL / DepMap), Structural Protein Intelligence (AlphaFold / ESM), Molecular Docking / QSAR evaluation, ADMET safety profiling, and Network-Based Drug Repurposing into an end-to-end computational pipeline. Every target or repurposing candidate is scored via a multi-dimensional harmonic ranking combining genetic validity, structural druggability, clinical safety, and GraphRAG mechanistic paths.

---

## 1. Multi-Dimensional Target Prioritization Index (TPI)

To evaluate whether a biological target $T$ should be advanced for drug design against disease $D$, BioDiscovery computes the **Target Prioritization Index (TPI)**:
$$\text{TPI}(T, D) = w_g S_{\text{genetics}} + w_d S_{\text{druggability}} + w_l S_{\text{literature}} - w_t S_{\text{toxicity}}$$
Where:
- $S_{\text{genetics}} \in [0, 1]$: Human genetic evidence score (ClinVar pathogenicity / Open Targets association).
- $S_{\text{druggability}} \in [0, 1]$: Structural pocket score and small-molecule tractability.
- $S_{\text{literature}} \in [0, 1]$: Normalized citation density and mechanistic claim support.
- $S_{\text{toxicity}} \in [0, 1]$: Pan-tissue expression penalty and known adverse event risk.

---

## 2. Mechanistic Drug Repurposing Pipeline

```
[Target Disease: Non-Small Cell Lung Cancer (MONDO:0005233)]
                             │
                             ▼
     1. Disease Pathway & Target Gene Profiling (EGFR / KRAS / ALK)
                             │
                             ▼
     2. Graph Mining for Existing Approved Drugs (ChEMBL / RxNorm)
     ├── Traverses BioKG: Drug ─[INHIBITS]─► Target Gene ─[TREATS]─► Disease
     └── Excludes Drugs with High ADMET Cardiotoxicity / Hepatotoxicity
                             │
                             ▼
     3. Multi-Hop Evidentiary Proof & Ranking Score Emission
```

---

## 3. Executable Python Contract for BioDiscovery

```python
import uuid
from datetime import datetime, timezone
from typing import List, Optional, Literal
from pydantic import BaseModel, Field


class ADMETSafetyProfile(BaseModel):
    """Absorption, Distribution, Metabolism, Excretion & Toxicity envelope."""
    hepatotoxicity_risk: Literal["LOW", "MODERATE", "HIGH"] = "LOW"
    cardiotoxicity_hERG_risk: Literal["LOW", "MODERATE", "HIGH"] = "LOW"
    blood_brain_barrier_permeable: bool = False
    oral_bioavailability_score: float = Field(0.85, ge=0.0, le=1.0)


class TargetPrioritizationCandidate(BaseModel):
    """Scored biological target candidate for a clinical indication."""
    candidate_id: uuid.UUID = Field(default_factory=uuid.uuid4)
    target_gene_urn: str
    disease_urn: str
    genetic_evidence_score: float = Field(..., ge=0.0, le=1.0)
    structural_druggability_score: float = Field(..., ge=0.0, le=1.0)
    literature_support_score: float = Field(..., ge=0.0, le=1.0)
    admet_profile: ADMETSafetyProfile
    composite_tpi_score: float = Field(..., ge=0.0, le=1.0)
    generated_at: datetime = Field(default_factory=lambda: datetime.now(timezone.utc))
```
